Ultrasound is a form of energy that can pass through skin, muscle, fat and other soft tissue so no incisions or inserted probes are needed. High intensity focused ultrasound (HIFU) pinpoints a small target and provides a therapeutic effect by raising the temperature high enough to destroy the target with no damage to surrounding tissue.
Magnetic resonance imaging (MRI) is used to guide and control the treatment, which is performed while you lie in an MR scanner. Guided by detailed images of your anatomy and the tumour, the physician is able to pinpoint, direct and continuously monitor the treatment.
The ExAblate Neuro is intended for use in the unilateral Thalamotomy treatment of idiopathic Essential Tremor patients with medication-refractory tremor. Patients must be at least age 22.
The designated area in the brain responsible for the movement disorder symptoms (ventralis intermedius) must be identified and accessible for targeted thermal ablation by the ExAblate device.
Advantages
The device may reduce moderate to severe medication-refractory motor complications in patients when used as a supplement to Parkinson’s disease medication treatment.
The ExAblate Model 4000 System (ExAblate Neuro) is a magnetic resonance image-guided focused ultrasound (MRgFUS) system that treats tremors that cannot be controlled using medication alone in essential tremor and tremor-dominant Parkinson’s disease patients by destroying areas of brain tissue.
Magnetic resonance guided focused ultrasound (MRgFUS) is a non-invasive way to treat benign and malignant tumours.
Insightec, a global healthcare company focused on transforming patient care, announced its incisionless neurosurgery platform, the ExAblate® 4000, has received market approval by the Central Drugs Standard Control Organization (CDSCO), part of the Ministry of Health and Family Welfare of India.
This approval in India adds to the growing recognition of the value of Focused Ultrasound for global healthcare systems.
